Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system

Immunotherapy for malignant tumors is a hot spot in current research and the treatment of cancer. The activation of programmed cell death receptor‐1 (PD‐1) and cytotoxic T lymphocyte‐associated antigen 4 (CTLA)‐4 relevant signaling pathway can inhibit the activation of T lymphocytes. Tumor cells can...

Full description

Bibliographic Details
Main Authors: Yue Li, Xiaohui Kang, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Li Zhang, Xiaowei Liu, Jiaming Qian
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Thoracic Cancer
Subjects:
Gastrointestinal adverse events
hepatic toxicity
immune‐checkpoint inhibitors
immune‐related adverse events
Online Access:https://doi.org/10.1111/1759-7714.13338

Internet

https://doi.org/10.1111/1759-7714.13338

Similar Items